Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578118 | 0.71 | CES2 (0.37) | CA1CA12CES2CES1 | |
| SCHEMBL2347207 | 0.71 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL6736521 | 0.68 | TDP1 (0.31) | — | |
| SCHEMBL1445878 | 0.67 | — | — | |
| SCHEMBL22342296 | 0.67 | TSHR (0.35) | — | |
| SCHEMBL29610239 | 0.67 | — | — | |
| SCHEMBL41646 | 0.66 | CA1 (0.43) | CA1CA2CA4CA12CA7 | |
| SCHEMBL7702552 | 0.66 | CA1 (0.43) | CA1CA2CA4CA12CA7 | |
| SCHEMBL439846 | 0.65 | CA1 (0.38) | CA1CA2CA4CA12CA7 | |
| SCHEMBL1445920 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135478-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-11-14 | — | — | US | disclosed |
| US-7012079-B1 | Optically pure camptothecin analogues | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-03-14 | — | — | US | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| EP-0995753-B1 | Method for manufacturing fluoroaryl magnesium halide | NIPPON CATALYTIC CHEM IND (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2003-01-02 | — | — | US | disclosed |
| US-6235222-B1 | REACTING, IN SOLVENT CONTAINING CHAIN ETHER SOLVENT, HYDROCARBON MAGNESIUM HALIDE WITH FLUOROARYL HALIDE | NIPPON SHOKUBAI CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0995753-A2 | Method for manufacturing fluoroaryl magnesium halide | Nippon Shokubai Co., Ltd. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP1, TOP2A, TYMP | CA1 3737/4885CA2 4145/4885CA4 1894/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | CA1 912/4885CA2 2881/4885CA4 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.